Table 3.
Univariate and multivariate analyses of HCC recurrence after DAA therapy in all patients
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95% CI) | P‐value | HR (95% CI) | P‐value | |
| Age before DAA therapy (by every 10 y) | 0.986 (0.827‐1.179) | 0.8841 | 0.982 (0.747‐1.291) | 0.8992 |
| Sex (female) | 1 | 1 | ||
| (male) | 1.340 (1.019‐1.774) | 0.0357 | 1.355 (0.958‐1.926) | 0.0854 |
| AST level before DAA therapy (by every 10 IU/L) | 1.033 (0.991‐1.073) | 0.1055 | 1.066 (0.937‐1.212) | 0.3290 |
| ALT level before DAA therapy (by every 10 IU/L) | 1.018 (0.976‐1.058) | 0.3802 | 0.996 (0.877‐1.131) | 0.9535 |
| GGTP level before DAA therapy (by every 10 IU/L) | 0.995 (0.965‐1.018) | 0.7610 | 0.996 (0.950‐1.044) | 0.8872 |
| Platelet count before DAA therapy (by every 104/μL) | 0.952 (0.922‐0.981) | 0.0019 | 0.995 (0.941‐1.053) | 0.8840 |
| AFP level before DAA therapy (by every 10 ng/mL) | 1.019 (1.003‐1.031) | 0.0046 | 1.021 (1.006‐1.036) | 0.0062 |
| APRI before DAA therapy (by every 1 unit) | 1.078 (1.009‐1.147) | 0.0195 | 0.835 (0.561‐1.243) | 0.3756 |
| FIB‐4 index before DAA therapy (by every 1 unit) | 1.040 (1.011‐1.067) | 0.0044 | 1.054 (0.912‐1.218) | 0.4718 |
| Geno/serotype (1) | 1 | 1 | ||
| (2) | 1.396 (0.904‐2.066) | 0.1270 | 1.128 (0.664‐1.917) | 0.6543 |
| Habitual alcohol intake (absence) | 1 | 1 | ||
| (presence) | 1.384 (0.929‐1.999) | 0.1067 | 1.315 (0.799‐2.165) | 0.2808 |
| Diabetes mellitus (absence) | 1 | 1 | ||
| (presence) | 0.975 (0.716‐1.311) | 0.8738 | 0.939 (0.637‐1.358) | 0.7440 |
| Fatty liver (absence) | 1 | 1 | ||
| (presence) | 1.019 (0.585‐1.652) | 0.9407 | 1.078 (0.569‐1.897) | 0.8048 |
| Cirrhosis (absence) | 1 | 1 | ||
| (presence) | 1.696 (1.240‐2.363) | 0.0007 | 1.332 (0.871‐2.086) | 0.1883 |
| Number of curative treatments for HCC before DAA therapy (1) | 1 | 1 | ||
| (2) | 1.539 (1.074‐2.170) | 0.0191 | 1.608 (1.054‐2.407) | 0.0277 |
| (3 or more) | 2.561 (1.878‐3.476) | <0.0001 | 2.610 (1.762‐3.843) | <0.0001 |
AFP, alpha‐fetoprotein; ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet count ratio index; AST, aspartate aminotransferase; CI, confidence interval; DAA, direct‐acting antiviral agents; FIB‐4 index, Fibrosis‐4 index; GGTP, gamma‐glutamyl transpeptidase; HCC, hepatocellular carcinoma; HR, hazards ratio.